2001 Financial Markets Preview

Looking for news flow

Key product approvals and good pivotal data could keep investors in the game in 2001. The biotech industry appears to be deep on both counts.

Closely watched FDA marketing decisions for 2001 include several for Amgen Inc. (AMGN, Thousand Oaks, Calif.): IL-1ra recombinant anti-inflammatory protein to treat patients with rheumatoid arthritis; Abarelix depot luteinizing hormone releasing hormone (LHRH)/gonadotropin releasing hormone (GnRH) antagonist to treat prostate cancer, and novel erythropoiesis stimulating protein (NESP) for use in patients with chronic renal insufficiency and chronic renal failure. AMGN is developing abarelix with

Not short on data